Anavex Life Sciences Reports Fiscal 2020 Third Quarter Financial Results And Provides Business Updates August 6, 2020
Anavex Life Sciences Reports Fiscal 2020 Third Quarter Financial Results And Provides Business UpdatesAugust 6, 2020
Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX®2-73 (blarcamesine) for Alzheimer’s Disease PatientsAugust 5, 2020
Anavex Life Sciences to Announce Fiscal 2020 Third Quarter Financial Results on Thursday, August 6th, 2020August 4, 2020
Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)July 6, 2020
Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical TrialJune 16, 2020
Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s DiseaseJune 4, 2020
Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)May 21, 2020
Anavex Life Sciences Reports Fiscal 2020 Second Quarter Financial Results And Provides Business UpdatesMay 7, 2020
Anavex Life Sciences to Announce Fiscal 2020 Second Quarter Financial Results on Thursday, May 7th, 2020May 5, 2020
Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19March 31, 2020
Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results And Provides Clinical Study UpdatesFebruary 6, 2020
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study UpdatesDecember 16, 2019
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019December 10, 2019
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer’s Disease (CTAD) 2019 ConferenceDecember 4, 2019
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment of Rett SyndromeNovember 14, 2019
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease October 9, 2019
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’s DiseaseOctober 2, 2019
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare ConferenceSeptember 26, 2019
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare ConferenceSeptember 18, 2019
Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results and Provides Clinical Study UpdatesAugust 7, 2019
Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday August 7th, 2019August 2, 2019
Anavex Life Sciences Announces First Patient Dosed in Extension Study to its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients for Rett SyndromeJune 25, 2019
Anavex Life Sciences Announces First Patient Dosed in Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Rett Syndrome (AVATAR)June 6, 2019
Rett Syndrome Association of Australia and Anavex Life Sciences Announce Initiation of the Phase 2 AVATAR Clinical Study in Patients with Rett SyndromeMay 8, 2019
Anavex Life Sciences Reports Fiscal 2019 Second Quarter Financial Results And Provides Clinical Study UpdatesMay 8, 2019
Anavex Life Sciences to Announce Fiscal 2019 Second Quarter Financial Results on Wednesday May 8th, 2019May 6, 2019
Anavex Life Sciences to Present at the H.C. Wainwright Annual Global Life Sciences ConferenceApril 5, 2019
Anavex Life Sciences Presents Data On ANAVEX®2-73 in Alzheimer’s Disease at the American Society for Experimental Neurotherapeutics – ASENT 2019 Annual MeetingMarch 28, 2019
Anavex Life Sciences Announces First Patient Dosed in Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Rett Syndrome in the U.S.March 18, 2019
Anavex Life Sciences Reports Fiscal 2019 First Quarter Financial Results And Provides Clinical Study UpdatesFebruary 7, 2019
Anavex Life Sciences to Announce Fiscal 2019 First Quarter Financial Results on Thursday, February 7th, 2019January 31, 2019
Anavex Life Sciences Reports Fiscal Year 2018 Financial Results And Provides Clinical Study UpdateDecember 12, 2018
Anavex Life Sciences to Announce 2018 Fiscal Year End Financial Results on Wednesday, December 12, 2018December 10, 2018
Anavex Life Sciences Strengthens its Scientific Advisory Board with Distinguished Researcher for Clinical Treatment of Parkinson’s Disease Dementia (PDD)November 8, 2018
First Patient Enrolled in Anavex Life Sciences Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Parkinson’s Disease Dementia (PDD)October 30, 2018
Anavex Life Sciences Presents New Three-Year, Longitudinal Clinical Efficacy Data for ANAVEX®2-73 in Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) MeetingOctober 26, 2018
Anavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX®2-73 in Patients with Rett SyndromeOctober 19, 2018
Anavex Life Sciences to Present at the 2018 Cantor Fitzgerald Global Healthcare ConferenceSeptember 26, 2018
First Patient Enrolled in Anavex Life Sciences Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s DiseaseAugust 28, 2018
Anavex Life Sciences to Announce Fiscal Third Quarter 2018 Financial Results on Thursday, August 9, 2018August 7, 2018
Anavex Life Sciences Presents New Data Identifying Treatment Response Biomarkers in Alzheimer’s Disease Patients Treated with Investigational ANAVEX®2-73 at 2018 Alzheimer’s Association International Conference (AAIC)July 25, 2018
Anavex Life Sciences Receives Approval to Initiate Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Parkinson’s Disease DementiaJuly 9, 2018
Anavex Life Sciences Receives Approval To Initiate Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s DiseaseJuly 3, 2018
Anavex Life Sciences to Announce Fiscal Second Quarter 2018 Financial Results on Thursday, May 10, 2018May 9, 2018
Anavex Life Sciences to Initiate Phase 2 Study of ANAVEX®2-73 in Parkinson’s Disease Dementia and Provides Clinical Study Update for ANAVEX®2-73 in Rett SyndromeApril 17, 2018
Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT)March 7, 2018
Anavex Life Sciences Provides Clinical Programs Update and Reports Fiscal First Quarter 2018 Financial ResultsFebruary 7, 2018
Anavex Life Sciences to Announce Fiscal First Quarter 2018 Financial Results and Provide an Update on Clinical Programs and Corporate Highlights on Wednesday, February 7, 2018February 5, 2018
Anavex Life Sciences to Present at the Noble Capital Markets 14th Annual Institutional Investor ConferenceJanuary 24, 2018
Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic ProgramsDecember 11, 2017
5th Annual Mental health Parity Addiction Equity Act Business Roundtable in Washington DC on November 8, 2017November 6, 2017
Anavex® Life Sciences presenting at Society for Neuroscience Nov. 11-15, 2017 in Washington DCNovember 6, 2017
Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017October 27, 2017
Anavex President & CEO Christopher U. Missling, PhD, to present preclinical data on ANAVEX 2-73™ at the Epilepsy Foundation’s Antiepileptic Drug Trials XIV Conference on May 19.May 17, 2017
Anavex President & CEO Christopher U. Missling, PhD, to participate in a roundtable discussion at the World Orphan Drug Congress USA, on April 21.April 21, 2017
Anavex Life Sciences to Present at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases AD/PD™ 2017March 29, 2017
BIO CEO & Investor Conference 2017 Panel “Designing Clinical Trials in 21st Century Cures Paradigm”February 9, 2017
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016January 14, 2016
